Journal papers & other resources

Shared by CancerCare:  

https://media.cancercare.org/ublications/original/386-2018_Lung_Cancer_Roundtable.pdf

(Authors include Carolyn ‘Bo’ Aldigé, work supported by Winfield Boerckel)

More Than a Partnership: How Oncogene-Driven Patient Groups Are Mobilizing the Global Community to Drive Research – ILCN.org (ILCN/WCLC)

Oncogene-specific advocacy groups bring a patient-centric perspective to studies of lung cancer (nature.com)

Lung Health Foundation (Canada):

Targeted Lung Cancer Therapies – Precision Medicine Whitepaper. 

New Treatment Options for Patients With Oncogene-Addicted Non–Small Cell Lung Cancer Focusing on EGFR-Mutant Tumours

Authors: Stephanie P.L. Saw, MBBS, MRCP, Xiuning Le, MD, PhD, Lizza E.L. Hendriks, MD, PhD, and Jordi Remon, MD, PhD

https://orcid.org/0000-0002-9462-875

Publication: American Society of Clinical Oncology Educational Book

Volume 44, Number 3

https://doi.org/10.1200/EDBK_432516

 

ALK+ Journal Papers and Publications 

The following publication was co-developed by medical experts in oncology (physicians and nursing background) and ALK+ patients:

The Lung Cancer Journal Publication (open source): Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts

   

A newsletter by Nancee Pronsati, the lead author of this publication on the ALK+ Positive patient advocacy group: Managing Lorlatinib Together: What Patients and Experts Want You to Know

 

ALK+ Lung Cancer UK shared the following: 

Immunotherapy doesn’t tend to work in ALK+ lung cancer. New research may explain why, and what could change that.

Two papers in Cancer Immunology Research looked at the immune environment of ALK+ lung adenocarcinoma. They found ALK+ tumours often build an immune-suppressing “shield” made up of cells that protect the tumour rather than attack it. High IL-6 signalling seems to drive this.

In lab studies, blocking IL-6 alongside a PD-(L)1 immunotherapy changed that environment, let immune cells attack the tumour, and controlled growth.

This is early-stage research. It helps explain the limited benefit of checkpoint inhibitors in ALK+ disease and points to a possible future strategy.

📄 Vitale & Bria, 2025; Arai et al., 2025 — Cancer Immunology Research

Unlocking the Immune Response in ALK-Rearranged Lung Adenocarcinoma 

Authors: Antonio Vitale and Emilio Bria Corresponding Author
Publication: Cancer Immunology Research (online)
In the Spotlight| August 08 2025

See related article by Arai et al.

MET – Key article in Journal of Thoracic Oncology (JTO) August 2025

Cover Image - Journal of Thoracic Oncology, Volume 20, Issue 8
Commentary Volume 20, Issue 8 p1032-1034 August 2025
Misleading Interpretations of the MET Gene Acronym: Over 15 Years of Confusion in Scientific Publications and a Call for Reaffirming the Original Gene Nomenclature
apiotr.religa@ki.se ∙ b ∙ b ∙ b,c
In the reference of a article entitled: “MET exon 14 skipping mutations in lung adenocarcinoma: clinicopathologic implications and prognostic values” by Lee et al., we would like to rise a longstanding issue of misinterpretation and misuse of the MET gene acronym, that has persisted across numerous scientific papers on cancer research over the past 15 years, with virtually no efforts made to correct or address this recurring problem.
We have found only one corrigendum on this matter. The correction of past inaccuracy is commendable. Nevertheless, it raises a broader and persistent problem: the widespread propagation of an erroneous interpretation of the MET gene acronym with an insistently amplified, wrong full name meaning of the abbreviation as mesenchymal epithelial transition factor, gene or protein in research articles.
As search results in PubMed database show, initially, the phrase “mesenchymal epithelial transition factor” likely appeared in 2008, and since then, it has been repeated in over 500 scientific publications in relation to gene name “MET” (Fig. 1). This term misrepresents the function of the MET gene, perpetuating confusion within both academic and clinical contexts. To our knowledge, no prior corrigenda have been issued to correct earlier misinterpretations in other publications, further emphasizing the need for clarity on this matter.

Fundacion Pacientes de Cancer de Pulmon video discussing importance of biomarkers, in Spanish

View video here: https://youtu.be/tcZc96LgDps

 

Informative article about NSCLC, biomarkers and treatments from Boehringer Ingelheim website:

https://www.boehringer-ingelheim.com/human-health/cancer/lung-cancer/non-small-cell-lung-cancer-nsclc

Mainstream media  

Key BBC Future – Health – article about rise of LC among non-smokers:
https://www.bbc.co.uk/future/article/20250605-the-mystery-rise-of-lung-cancer-in-non-smokers

 

global
RESEARCH - The State of Global Lung Cancer Research - 2020 data now published / NEWS - global COVID-19 updates
View